In a pilot study, a novel regimen showed 100% disease control in 5 patients with recurrent GBM, with 2 achieving near ...

Incorporating molecular classification into preoperative staging for endometrial cancer improved risk stratification in ...

FDA breakthrough therapy designation granted for rinatabart sesutecan in endometrial cancer, based on encouraging data from a ...

Binod Dhakal, MD, discusses using a variety of combination therapies as bridging or later-line options for patients with relapsed myeloma.

This is the AGAVE-201 trial [NCT04710576]. It was a phase 2 randomized trial, and they looked at 3 different dosing schedules ...

The FDA has granted breakthrough device designation to the Haystack MRD test, a circulating tumor DNA (ctDNA) test, for use ...

Over 150 oncologists choose their preference for combination regimens in metastatic ccRCC based on current data in the ...

Innovent's bispecific antibody, IBI363, enters a global phase 3 trial for IO-resistant lung cancer, the first of its kind, ...

A study compares second-look laparoscopy and circulating tumor DNA (ctDNA) to detect residual ovarian cancer and predict ...

Shifting from a tumor-centric to a patient-centric approach is key for older cancer patients, focusing on functional capacity ...

Dordaviprone received accelerated FDA approval for H3 K27M-mutant diffuse midline glioma, an aggressive brain tumor, making ...

A study shows talquetamab is a safe, effective bridge for high-risk patients, potentially improving outcomes and mitigating ...